LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) Free cash flow 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$48.9MFY2025 · since FY2016: $58.9M → $48.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $48.9M | -48.6% |
| FY2024 | $95.2M | +106.8% |
| FY2023 | $46.1M | -61.6% |
| FY2022 | $119.9M | +71.2% |
| FY2021 | $70.0M | +39.7% |
| FY2020 | $50.1M | +257.2% |
| FY2019 | -$31.9M | -116.5% |
| FY2018 | $193.2M | +123.5% |
| FY2017 | $86.4M | +46.8% |
| FY2016 | $58.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice